The clinical experience with Graceptor in de novo renal transplant patients and retrospective study of pharmacokinetics

The clinical experience with Graceptor in de novo renal transplant patients and retrospective study of pharmacokinetics - The clinical experience with Graceptor in de novo renal transplant patients and retrospective study of pharmacokinetics

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003058

Enrollment

Registered

2010-01-19

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with end-stage renal disease which were received a kidney transplant from a living donor at Gifu University Hospital.

Exclusion criteria

Exclusion criteria: previous history of organ transplantation woman during pregnacy

Design outcomes

Primary

Measure	Time frame
OD TAC is a safe and effective addition to the existing therapeutic options for de novo renal transplant, but we think that target trough levels should be readjusted. Monitoring of trough levels provides a good estimate of systemic exposure.	—

Countries

Japan

Contacts

Public ContactKenichiro Ishida

gifu university urology

058-230-6338

Outcome results